The New York Times 
(12/13, D6, Bakalar, Subscription Publication) reports an
observational study published online in the Annals of Surgery finding
that "even though their health was generally poorer," cardiac patients
who took aspirin before heart surgery "fared better," with "a lower risk
of renal failure, a shorter stay in the intensive care unit, a reduced
risk of major cardiac problems and a significant decrease in the risk
for death in the month after the procedure." Currently, guidelines
recommend people not take aspirin the week
before surgery due to an increased risk of bleeding. The authors
suggest that aspirin's anti-inflammatory properties are related to
positive outcomes.
(12/13, D6, Bakalar, Subscription Publication) reports an
observational study published online in the Annals of Surgery finding
that "even though their health was generally poorer," cardiac patients
who took aspirin before heart surgery "fared better," with "a lower risk
of renal failure, a shorter stay in the intensive care unit, a reduced
risk of major cardiac problems and a significant decrease in the risk
for death in the month after the procedure." Currently, guidelines
recommend people not take aspirin the week
before surgery due to an increased risk of bleeding. The authors
suggest that aspirin's anti-inflammatory properties are related to
positive outcomes.
Study: Aspirin Safe, Low-Cost Recurrent VTE Prevention After Anticoagulation Stopped.
In continuing coverage, HeartWire
(12/13, O'Riordan) reports a study presented at the American Society of
Hematology 2011 Annual Meeting found that "aspirin reduces the risk of
recurrent venous thromboembolism (VTE) by more than half when compared
with placebo" and is not accompanied by an increased risk of bleeding.
The investigators said that this "makes aspirin an attractive treatment
option for the extended prevention of recurrent VTE once oral
anticoagulation has been stopped."
Investigators noted that aspirin "is a practical, low-cost option for
clinicians and patients, even though it is not as efficacious for the
reduction of recurrent VTE as other agents."
(12/13, O'Riordan) reports a study presented at the American Society of
Hematology 2011 Annual Meeting found that "aspirin reduces the risk of
recurrent venous thromboembolism (VTE) by more than half when compared
with placebo" and is not accompanied by an increased risk of bleeding.
The investigators said that this "makes aspirin an attractive treatment
option for the extended prevention of recurrent VTE once oral
anticoagulation has been stopped."
Investigators noted that aspirin "is a practical, low-cost option for
clinicians and patients, even though it is not as efficacious for the
reduction of recurrent VTE as other agents."
No comments:
Post a Comment